60.9 F
San Diego
Wednesday, Oct 4, 2023



Aurora Biosciences Corp.

Aurora Biosciences Corp. designs, develops and sells proprietary drug discovery systems, services and technologies to accelerate and enhance the discovery of new medicines by the pharmaceutical and biopharmaceutical industries.


- Advertisement -

Total number of shares outstanding as of Dec. 21, 1999 17,300,000

Price of each share of common stock as of Dec. 21, 1999 $16.625

Aggregate market value as of Dec. 21, 1999 $287,612,500

Performance Record

For year ended Dec. 31, in thousands, except per-share data

1998 1997 1996

Revenues $26,538 $14,908 $2,217

Net income (loss) $(18,653) $267 $(2,933)

Net income (loss) per share $(1.14) $0.02 $(3.86)

Total assets $50,955 $63,036 $17,515


Timothy J. Rink, 52, served as chairman, president and CEO since January 1996. He is also a director of CoCensys, Inc., a biopharmaceutical company.

James C. Blair, 59, has been director since March 1996. He has been a managing member of Domain Associates, LLC, a venture capital firm, since 1985. He is also a director of Amylin Pharmaceuticals, Inc., Trega Biosciences, Inc. and Vista Medical Technologies, Inc.

Kevin J. Kinsella, 53, has been a founder and director since its inception in May 1995. He is the chairman, CEO and president of ANCILE Pharmaceuticals, Inc.

Hugh Y. Rienhoff Jr., 46, has been director since March 1996. He has been the CEO of Kiva Genetics, Inc., since September 1998. He is also a director of Microcide Pharmaceuticals, Inc.

Lubert Stryer, 61, has been a director since March 1996 and serves as a scientific advisor. He is a Winzer professor in the School of Medicine and professor of neurobiology at Stanford University. He is also a director of Affymetrix, Inc.

Roy A. Whitfield, 45, has been a director since September 1997. Since June 1993, he has been CEO of Incyte Pharmaceuticals, Inc.

Timothy J. Wollaeger, 55, has been a director since March 1996. Since 1993, he has been a general partner of Kingsbury Associates; Kingsbury Capital Partners, LP; Kingsbury Capital Partners, LP II; and Kingsbury Capital Partners, LP III, all venture capital investment firms.

Executive Compensation

Officers Cash Compensation

Timothy Rink, president, CEO and chairman $425,012

Paul Grayson, senior vice president of corporate development $231,667

Harry Stylli, senior vice president of screen technology and new

technology ventures $214,417

Paul England, senior vice president of research $191,686

John Mendlein, vice president of intellectual property and senior legal counsel $203,333

Significant Stock Ownership

Number of shares Percent

March 8, 1999

The Kaufmann Fund, Inc. 3,002,000 17.6

BB Biotech and affiliates 1,421,500 8.3

Directors and officers as a group 1,761,513 10.2

Other Information

Headquarters: 11010 Torreyana Road, San Diego CA 92121; (858) 404-6600; (858) 404-6714; (www.aurorabio.com)

Auditors: Ernst & Young LLP, San Diego

Information was compiled from the company’s annual and proxy reports.


Featured Articles


Related Articles